Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT07282834

Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)

Led by Patrick Wagner, MD, FACS · Updated on 2026-02-27

200

Participants Needed

1

Research Sites

773 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research study aims to improve the treatment of Peritoneal Carcinomatosis (PC), a condition where cancer spreads within the abdomen. Patients with PC often experience significant pain and nutritional problems. Currently, there isn't a standard treatment approach, and doctors use different combinations of chemotherapy, surgery, and methods to deliver chemotherapy directly into the abdomen (intra-peritoneal or "IP" chemotherapy). The study will compare two IP chemotherapy methods: HIPEC and PIPAC. HIPEC involves circulating heated chemotherapy through the abdomen during surgery, while PIPAC delivers chemotherapy as a pressurized aerosol during a laparoscopic procedure. Both methods aim to achieve the same goal, but they haven't been directly compared to see which is safer, more tolerable, more effective, and provides better value.

CONDITIONS

Official Title

Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males or females age 18 to 80 years.
  • Biopsy-proven or clinically suspected peritoneal carcinomatosis.
  • Received at least three months of standard systemic chemotherapy with persistent disease at randomization.
  • Not a candidate for surgical cytoreduction at time of laparoscopy.
  • Women of childbearing potential must have a negative pregnancy test and use contraception during the study.
  • Ability to read, understand English, and consent for themselves.
Not Eligible

You will not qualify if you...

  • Eligible for definitive cytoreductive surgery at enrollment.
  • Significant blood, liver, or kidney abnormalities as defined by specific laboratory values.
  • Use of investigational drugs within 30 days before enrollment.
  • Systemic therapy within 14 days before randomization.
  • Allergy or contraindication to the chemotherapy used.
  • Medical contraindication to laparoscopic or complex cytoreductive surgery.
  • Pregnant or breastfeeding females.
  • Likely non-compliance with study procedures as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Allegheny Health Network West Penn Hospital

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

Loading map...

Research Team

P

Patrick Wagner, MD

CONTACT

A

AHN Clinical Trial Contact Clinical Trial Contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here